Literature DB >> 29980819

[Pancreatic ductal adenocarcinoma].

E Gallmeier1, T M Gress2.   

Abstract

Pancreatic ductal adenocarcinoma represents the most common malignant tumor of the pancreas. Despite substantial research efforts and gradual diagnostic and therapeutic improvements, its prognosis remains dismal. In accordance with the current German, European, and US guidelines, this CME-article provides a comprehensive review of the disease. In addition, selected up-to-date aspects of epidemiology, etiopathology, genetics, and basic principles of diagnostics and therapy including potential future therapeutic options are discussed.

Entities:  

Keywords:  Diagnosis; Etiopathology; Genetics; Pancreatic cancer; Therapy

Mesh：

Year:  2018        PMID： 29980819     DOI： 10.1007/s00108-018-0460-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  86 in total

1.  Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis.

Authors:  Shandra Bipat; Saffire S K S Phoa; Otto M van Delden; Patrick M M Bossuyt; Dirk J Gouma; Johan S Laméris; Jaap Stoker
Journal:  J Comput Assist Tomogr       Date:  2005 Jul-Aug       Impact factor: 1.826

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Authors:  Maeve A Lowery; Emmet J Jordan; Olca Basturk; Ryan N Ptashkin; Ahmet Zehir; Michael F Berger; Tanisha Leach; Brian Herbst; Gokce Askan; Hannah Maynard; Danielle Glassman; Christina Covington; Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; David S Klimstra; Jaclyn F Hechtman; David M Hyman; Peter J Allen; William R Jarnagin; Vinod P Balachandran; Anna M Varghese; Mark A Schattner; Kenneth H Yu; Leonard B Saltz; David B Solit; Christine A Iacobuzio-Donahue; Steven D Leach; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2017-07-28       Impact factor: 12.531

4.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Authors:  Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

Review 5.  Familial pancreatic cancer.

Authors:  Gloria M Petersen
Journal:  Semin Oncol       Date:  2016-09-22       Impact factor: 4.929

6.  PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.

Authors:  Sharlene Gill; Yoo-Joung Ko; Christine Cripps; Annie Beaudoin; Sukhbinder Dhesy-Thind; Muhammad Zulfiqar; Pawel Zalewski; Thuan Do; Pablo Cano; Wendy Yin Han Lam; Scot Dowden; Helene Grassin; John Stewart; Malcolm Moore
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

7.  Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.

Authors:  Jee-Eun Kim; Kyu Taek Lee; Jong Kyun Lee; Seung Woon Paik; Jong Chul Rhee; Kyoo Wan Choi
Journal:  J Gastroenterol Hepatol       Date:  2004-02       Impact factor: 4.029

Review 8.  Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.

Authors:  Arndt Vogel; Frank Kullmann; Volker Kunzmann; Salah-Eddin Al-Batran; Helmut Oettle; Ruben Plentz; Jens Siveke; Christoph Springfeld; Hanno Riess
Journal:  Oncol Res Treat       Date:  2015-10-20       Impact factor: 2.825

9.  Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

Authors:  Juan W Valle; Daniel Palmer; Richard Jackson; Trevor Cox; John P Neoptolemos; Paula Ghaneh; Charlotte L Rawcliffe; Claudio Bassi; Deborah D Stocken; David Cunningham; Derek O'Reilly; David Goldstein; Bridget A Robinson; Christos Karapetis; Andrew Scarfe; Francois Lacaine; Juhani Sand; Jakob R Izbicki; Julia Mayerle; Christos Dervenis; Attila Oláh; Giovanni Butturini; Pehr A Lind; Mark R Middleton; Alan Anthoney; Kate Sumpter; Ross Carter; Markus W Büchler
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

10.  Adjuvant chemotherapy in elderly patients with pancreatic cancer.

Authors:  A M Nagrial; D K Chang; N Q Nguyen; A L Johns; L A Chantrill; J L Humphris; V T Chin; J S Samra; A J Gill; M Pajic; M Pinese; E K Colvin; C J Scarlett; A Chou; J G Kench; R L Sutherland; L G Horvath; A V Biankin
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640
View more
  5 in total

1.  The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction.

Authors:  Junjie Hang; Junjie Huang; Siyuan Zhou; Lixia Wu; Yingwei Zhu; Lina Zhu; Hanyu Zhou; Kequn Xu; Hua Jiang; Xuguang Yang
Journal:  Cancer Med       Date:  2019-02-14       Impact factor: 4.452

2.  Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling.

Authors:  Huimin Lu; Jun Ye; Ling Zhang; Mao Li; Shan Lu; Dujiang Yang; Weiming Hu
Journal:  Mol Med Rep       Date:  2019-09-24       Impact factor: 2.952

3.  A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Li-Xia Wu; Xiao-Yong Wang; Ke-Qun Xu; Yu-Li Lin; Wen-Yu Zhu; Long Han; Yue-Ting Shao; Han-Yu Zhou; Hua Jiang; Jun-Jie Hang; Xu-Guang Yang
Journal:  J Cancer       Date:  2019-10-22       Impact factor: 4.207

4.  Construction of a Competitive Endogenous RNA Network for Pancreatic Adenocarcinoma Based on Weighted Gene Co-expression Network Analysis and a Prognosis Model.

Authors:  Jing Wang; Jinzhu Xiang; Xueling Li
Journal:  Front Bioeng Biotechnol       Date:  2020-05-28

5.  MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma.

Authors:  Xing Wang; Yu-Qiang Shan; Qing-Quan Tan; Chun-Lu Tan; Hao Zhang; Jin-Heng Liu; Neng-Wen Ke; Yong-Hua Chen; Xu-Bao Liu
Journal:  Cancer Cell Int       Date:  2020-02-28       Impact factor: 5.722
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.